All In Biotech

BLA 125031 · Amgen

Neulasta

Pegfilgrastim · Leukocyte Growth Factor

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Jan 31, 2002

Approved uses

3

Original approval plus efficacy supplements

Registered trials

400

72 Phase 3, 30 recruiting

FAERS reports

98,636

28,802 serious, 5,283 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 5, 2026.

Neulasta is a leukocyte growth factor indicated in adult and pediatric patients to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). ( 1.2 ) Limitations of Use Neulasta is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy Neulasta is indicated in adult and pediatric patients to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Clinical Studies (14.1) ] . Limitations of Use Neulasta is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. 1.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome Neulasta is indicated to increase survival in adults and pediatric patients acutely exposed to myelosuppressive doses of radiation [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] .

Mechanism: Pegfilgrastim is a colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NEULASTA · PEGFILGRASTIM 6MG/0.6ML · SYRINGE, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pegfilgrastim" as an intervention, any sponsor and status, largest first.

All 400 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • device adhesion issue11,933
  • wrong technique in product usage process10,265
  • unintentional medical device removal8,999
  • device malfunction6,943
  • device use error6,057
  • device issue5,174
  • accidental exposure to product5,007
  • febrile neutropenia3,819
  • off label use3,795
  • device occlusion3,368
  • bone pain2,947
  • death2,771

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004346
2005350
2006391
2007595
2008910
2009945
2010883
20111,103
20121,563
20131,529
20142,667
20152,065
20165,281
20178,064
201814,149
20198,391
202011,660
202111,387
20228,427
20237,319
20245,726
20253,097
20261,788

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Neulasta (PEGfilgrastim)

2024 spending

$53.1M

Beneficiaries

2,421

7,279 claims

Per beneficiary

$21,942

$10,378.24 per unit

View as table
YearSpending
2020$41,020,941
2021$31,952,497
2022$36,058,073
2023$41,507,763
2024$53,122,083

Part B: Neulasta* (Pegfilgrastim*) · HCPCS J2506

2024 spending

$92.4M

Beneficiaries

34,572

120,210 claims

Per beneficiary

$2,672

2024 ASP limit $61.68 per unit

View as table
YearSpending
2020$0
2021$0
2022$341,605,921
2023$196,458,289
2024$92,382,519

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 309 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.